- Home
- ATON vs NERV Comparison
ATON vs NERV Comparison
Compare ATON & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATON
- NERV
- Stock Information
- Founded
- ATON 1973
- NERV 2007
- Country
- ATON British Virgin Islands
- NERV United States
- Employees
- ATON N/A
- NERV N/A
- Industry
- ATON Oil & Gas Production
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- ATON Energy
- NERV Health Care
- Exchange
- ATON Nasdaq
- NERV Nasdaq
- Market Cap
- ATON 13.4M
- NERV 12.0M
- IPO Year
- ATON N/A
- NERV 2014
- Fundamental
- Price
- ATON N/A
- NERV $2.25
- Analyst Decision
- ATON
- NERV Hold
- Analyst Count
- ATON 0
- NERV 1
- Target Price
- ATON N/A
- NERV $5.00
- AVG Volume (30 Days)
- ATON 86.9K
- NERV 21.0K
- Earning Date
- ATON 09-26-2025
- NERV 11-04-2025
- Dividend Yield
- ATON N/A
- NERV N/A
- EPS Growth
- ATON N/A
- NERV N/A
- EPS
- ATON N/A
- NERV 1.48
- Revenue
- ATON N/A
- NERV N/A
- Revenue This Year
- ATON N/A
- NERV N/A
- Revenue Next Year
- ATON N/A
- NERV N/A
- P/E Ratio
- ATON N/A
- NERV $1.47
- Revenue Growth
- ATON N/A
- NERV N/A
- 52 Week Low
- ATON $2.95
- NERV $1.15
- 52 Week High
- ATON $23.01
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- ATON N/A
- NERV 54.15
- Support Level
- ATON N/A
- NERV $2.26
- Resistance Level
- ATON N/A
- NERV $2.19
- Average True Range (ATR)
- ATON 0.00
- NERV 0.12
- MACD
- ATON 0.00
- NERV -0.03
- Stochastic Oscillator
- ATON 0.00
- NERV 45.65
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.